Naxitamab and Granulocyte–Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. This evidence concerns the gene CSF2 and neuroblastoma.